ARUP Laboratories Unveils Innovative Assay to Detect Influenza A (H5) Virus Outbreaks

ARUP Laboratories Introduces New Influenza A (H5) Virus Assay

In a significant advancement in public health diagnostics, ARUP Laboratories has launched a novel assay for the detection and subtyping of the Influenza A (H5) virus. This initiative comes in response to the increased outbreaks of H5N1, commonly referred to as bird flu, affecting poultry and dairy cattle across various states. The new test aims to support healthcare professionals in assessing individuals potentially exposed to this highly pathogenic avian influenza.

In early 2024, an alarming outbreak of H5N1 was reported in multiple poultry flocks and dairy herds. While primarily affecting birds, the potential for human infection has raised considerable concern. According to data from the Centers for Disease Control and Prevention (CDC), there have been 66 confirmed human cases of bird flu in the United States since April 2024, with one serious case in Louisiana requiring hospitalization.

Dr. Benjamin Bradley, the medical director at ARUP, emphasized the importance of remaining vigilant about this emerging health threat. “Most cases have resulted from exposure to infected animals, and thankfully, there is no evidence yet of human-to-human transmission,” he stated.

The newly developed test, known as the Influenza A (H5) Virus by Qualitative NAAT, or ARUP test number 3018970, has undergone rigorous validation in partnership with the CDC. Notably, ARUP was among the five designated CDC laboratory partners selected to refine the testing methods for avian influenza.

“Our collaboration with the CDC has led to the development of an innovative assay that significantly enhances our ability to identify this virus swiftly,” Bradley explained. He added that ARUP is committed to continuous monitoring of the H5 outbreak as it evolves, assuring that they will take proactive steps in addressing any new challenges that arise.

As a reputable national reference laboratory, ARUP Laboratories plays a crucial role in the public health landscape. They have been recognized for their timely and accurate testing services, which are essential in the response to emerging pathogens and infectious diseases. ARUP’s dedication to innovative diagnostic solutions is further evidenced through their Institute for Research and Innovation in Diagnostic and Precision Medicine, which focuses on advancing laboratory research and development.

Founded in 1984, ARUP Laboratories operates under the auspices of the University of Utah and its Department of Pathology, offering a comprehensive array of over 3,000 tests. These range from routine analyses to complex molecular and genetic tests, catering to various clients, including top-tier university teaching hospitals, major commercial laboratories, military facilities, and more.

In an era where public health is increasingly threatened by emerging infectious diseases, the introduction of the Influenza A (H5) virus assay by ARUP Laboratories marks a pivotal step in the effort to safeguard public health. This initiative not only boosts the country’s capabilities in dealing with outbreaks but also reinforces ARUP’s commitment to supporting healthcare providers in their critical work.

For more detailed information about the new assay, ARUP invites interested parties to visit their official website, where further insights into their testing methodologies and research initiatives can be explored.